Please try another search
For the three months ended 31 March 2016, Celator Pharmaceuticals Inc revenues was not reported. Net loss increased 17% to $5.5M. Higher net loss reflects General and administrative increase of 40% to $2.5M (expense), IE on Capital Financing, Gross increase of 34% to $459K (expense), Foreign exchange gain (loss) decrease from $10K (income) to $16K (expense).
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -5.06 | -4.62 | -4.72 | -4.48 |
Net Income | -5.53 | -4.41 | -5.21 | -4.98 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 69.41 | 25.64 | 26.75 | 32.12 |
Total Liabilities | 16.77 | 19.1 | 18.09 | 18.73 |
Total Equity | 52.63 | 6.53 | 8.66 | 13.38 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -5.11 | -15.49 | -13.32 | -9.01 |
Cash From Investing Activities | -0 | -0.06 | -0.04 | -0.03 |
Cash From Financing Activities | 49.4 | 6.42 | 5.08 | 5.13 |
Net Change in Cash | 44.29 | -9.16 | -8.31 | -3.93 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review